Shots:
- The companies collaborated to evaluate the safety, PK, PD & preliminary efficacy of the combination therapy of Innovent’s sintilimab + NeoCura’s NEO_PLIN2101 in patients with cancer
- The collaboration will bolster the clinical development of combination immunotherapy for multiple solid tumors & the companies plan to submit an IND application to the NMPA imminently
- Innovent is currently conducting 20+ clinical studies of sintilimab to assess safety and efficacy for multiple cancer indications including 10+ registrational or pivotal clinical trials. Additionally, sintilimab is currently under review in China & has one regulatory submission for the 1L treatment of ESCC
Click here to read full press release/ article | Ref: PR Newswire | Image: Linkedin
The post Innovent Entered into a Collaboration Agreement with NeoCura to Evaluate Sintilimab + NEO_PLIN2101 for Cancer in China first appeared on PharmaShots.
